As part of the UK’s Cell and Gene Therapy Catapult’s (CGT Catapult) work to support innovation in cell and gene therapies, their team needed to establish a robust viral vector workflow. To maximize viral vector output for clinical and commercial manufacturing applications, CGT Catapult sought to build a process using reliable products and scalable solutions, backed by access to industry expertise, to help navigate production challenges.
In this case study we explore how CGT Catapult developed a streamlined, optimized viral vector workflow to drive cell and gene therapy innovation forward.
Download our case study to learn about:
- Challenges associated with maximizing viral vector output
- Building an optimized, scalable viral vector workflow
- How CGT Catapult leveraged Thermo Fisher Scientific’s extensive product portfolio and expertise to create a process for AAV production